Impax Laboratories Inc (NASDAQ:IPXL) Amneal Pleased After FDA Approves Erythromycin Tablets

0

The stock of Impax Laboratories Inc (NASDAQ:IPXL) closed at $20.55 losing 0.96% in yesterday’s trading session. Amneal Pharmaceuticals LLC is quite pleased after it succeeded at obtaining the approval from FDA which gave it the go-ahead it needed to move ahead and continue with its efforts to market the Erythromycin Tablets USP, 250 mg and 500 mg strengths.

Arbor Pharmaceuticals is the manufacturer of Erythromycin Tablets which happen to be the therapeutic equivalent for the Amneal product. It is great news for struggling patients since they can now access the only other immediate release oral tablet and market observers have in one voice commended the various developments sweeping across the globe.

The Amneal EVP-Commercial Operations Andy Boyer has spoken in relation to the most recent developments terming them progressive and quite helpful in an era where a lot of people are struggling with difficult to treat medical conditions.

He opined, “Amneal is committed to increasing access to affordable medications. Erythromycin tablets are a great example of a product with limited availability where we can now provide patients and pharmacists with options.”

The move by Amneal to sell out its erythromycin tablets in the 100-count bottles will help in advancing care for patients since quite a significant number will afford the tablets. Reports indicate that at the moment they have been availed to wholesalers, distributors and direct to the trade and it goes without saying that the company is on the right track.

The results for the Annual U.S. sales of erythromycin tablets are already out and it has been reported that $84 million was accumulated and that was quite promising according to the market observers following closely on the matter.

It is easy to tell that the business guru so far has managed to accomplish quite much. At this point in time it takes immense pride in the fact that in now has to its side about 5,000 employees in Europe, Asia and North America. Looking back at the challenges it has encountered all along this is monumental success and it isn’t stopping there according to one of its executives. It plans to accomplish much more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here